<DOC>
	<DOCNO>NCT00001024</DOCNO>
	<brief_summary>Immunopathogenesis objective : To compare quantitatively determine HIV burden HIV replication peripheral blood ( PB ) lymphoid tissue ( LT ) . To determine degree antiretroviral therapy alters HIV replication LT. Clinical objective : To gain insight degree correlation immunologic surrogate marker HIV disease ( e.g. , CD4 , beta-2 microglobulin ) compare measure HIV replication PB LT. To assess change PB LT viral burden antiretroviral therapy determine ability predict antiviral response . One major problem define immunopathogenic change HIV infection inability correlate extent loss immunologic function number HIV-infected CD4+ cell peripheral blood . Few study exist measure viral burden lymph node HIV-infected individual . Researchers hope find whether amount HIV virus marker virus body 's lymph tissue well measure disease progression amount virus marker virus blood .</brief_summary>
	<brief_title>The Effects Anti-HIV Drugs HIV-Infected Patients Who Do Not Have AIDS</brief_title>
	<detailed_description>One major problem define immunopathogenic change HIV infection inability correlate extent loss immunologic function number HIV-infected CD4+ cell peripheral blood . Few study exist measure viral burden lymph node HIV-infected individual . Researchers hope find whether amount HIV virus marker virus body 's lymph tissue well measure disease progression amount virus marker virus blood . Sixteen antiretroviral-naive patient randomize either remain antiretroviral-naive ( treatment ) receive zidovudine daily ( treatment ) . Additionally , 16 patient 26 week ongoing zidovudine ( AZT ) therapy randomize either continue prestudy AZT regimen add didanosine ( ddI ) daily baseline AZT dose . Patients remain assigned treatment arm 8 week . A lymph node biopsy perform day 0 week 8 . Patients evaluate week 2 , 4 , 6 , 8 9 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis M. tuberculosis , therapy oral candidiasis , short course ( 10 day ) acyclovir herpes lesion . Antibiotics clinically indicate . Pneumococcal vaccine hepatitis B vaccine medically indicate . Regularly prescribed medication antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive , medication deem appropriate patient 's primary care provider . Recommended : PCP prophylaxis patient 's CD4 count fall 200 cells/mm3 study . Concurrent Treatment : Allowed : Alternative therapy vitamins acupuncture . Patients must : Documented HIV infection . At least two palpable lymph node waist . CD4 count &gt; = 350 cells/mm3 ( previously antiretroviralnaive ) &gt; = 250 cells/mm3 ( receive ongoing AZT therapy ) . Patients prior AZT therapy must receive stable dose 300600 mg daily 26 week . Prior Medication : Required patient prior ongoing therapy : AZT dose 300600 mg daily least 26 week . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Severe malabsorption . Current AIDSrelated opportunistic infection , AIDS dementia , AIDSwasting syndrome , AIDSrelated malignancy minimal Kaposi 's sarcoma disease . Current medical problem may interfere evaluation AZT increase potential toxicity AZT ( e.g. , significant liver disease , diabetes , significant cardiovascular disease , seizure disorder , lymphoma , acute chronic pancreatitis , febrile illness ) . Current diagnosis malignancy systemic therapy would require study . Concurrent Medication : Excluded : Ganciclovir , foscarnet , chronic acyclovir , probenecid . Other proven alleged antiretroviral antiHIV drug . Biologic response modifier . Valproic acid . Systemic cytotoxic chemotherapy . Steroids . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : Prior AIDSrelated opportunistic infection , AIDS dementia , AIDSwasting syndrome , AIDSrelated malignancy minimal Kaposi 's sarcoma disease . History medical problem may interfere evaluation AZT increase potential toxicity AZT ( e.g. , significant liver disease , diabetes , significant cardiovascular disease , seizure disorder , lymphoma , acute chronic pancreatitis , febrile illness ) . History peripheral neuropathy ( patient prior AZT treatment ) . Prior Medication : Excluded : Prior ddI therapy . Less 26 week prior AZT ( patient ongoing AZT therapy ) . Ganciclovir , foscarnet , chronic acyclovir , probenecid . Cytotoxic chemotherapy within 1 month prior study entry . Acute therapy infection medical illness within 14 day prior study entry . History alcohol abuse ( patient prior AZT treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lymph Nodes</keyword>
	<keyword>Lymphoid Tissue</keyword>
</DOC>